Related Experiment Video

Updated: Jul 18, 2026

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

Phase 2 trial of Allovectin-7 in advanced metastatic melanoma

Rene Gonzalez1, Laura Hutchins, John Nemunaitis

  • 1University of Colorado Cancer Center, Aurora, CO 80010-5010, USA. rene.gonzalez@uchsc.edu

Melanoma Research
|November 23, 2006
PubMed

Insights

Intralesional Allovectin-7 showed minimal adverse events in metastatic melanoma patients. This investigational therapy demonstrated biological activity and a favorable safety profile for potential dose escalation.

Area of Science:

  • Oncology
  • Immunotherapy
  • Gene Therapy

Background:

  • Metastatic melanoma treatment with chemotherapy yields poor outcomes.
  • Intralesional Allovectin-7, an HLA-B7/beta2 microglobulin plasmid, is a potential melanoma therapeutic.
  • Previous studies indicated Allovectin-7 is safe and well-tolerated.

Purpose of the Study:

  • To evaluate the safety and clinical activity of intralesional Allovectin-7 in patients with metastatic melanoma.
  • To determine response rates and duration of response for Allovectin-7 therapy.

Main Methods:

  • A phase 2, open-label, multi-center study.
  • Seventy-seven patients received 10 µg intralesional Allovectin-7 weekly for six weeks.
  • Clinical responses were assessed using World Health Organization criteria.

Main Results:

  • Allovectin-7 treatment was associated with minimal adverse events.
  • Seven patients (9.1%) achieved a complete or partial response.
  • The median duration of response was 4.8 months.

Conclusions:

  • Intralesional Allovectin-7 is safe and well-tolerated in metastatic melanoma patients.
  • The therapy demonstrated biological activity at the tested dose.
  • The favorable safety profile supports further investigation at higher doses for enhanced clinical activity.

More Related Videos

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...